Advisors Preferred LLC Makes New $3.95 Million Investment in Phibro Animal Health Corporation $PAHC

Advisors Preferred LLC purchased a new stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 96,886 shares of the company’s stock, valued at approximately $3,953,000. Advisors Preferred LLC owned about 0.24% of Phibro Animal Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in Phibro Animal Health by 2.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after acquiring an additional 363 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares in the last quarter. Prospera Financial Services Inc raised its position in shares of Phibro Animal Health by 3.6% in the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company’s stock valued at $508,000 after purchasing an additional 690 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Phibro Animal Health by 7.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 10,589 shares of the company’s stock valued at $428,000 after buying an additional 704 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Phibro Animal Health by 3.9% during the 3rd quarter. Federated Hermes Inc. now owns 23,062 shares of the company’s stock valued at $933,000 after buying an additional 859 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00. Following the completion of the sale, the chief executive officer directly owned 36,680 shares in the company, valued at $1,885,352. The trade was a 16.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 293,920 shares of company stock valued at $13,833,025 over the last quarter. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Trading Up 1.8%

Phibro Animal Health stock opened at $52.80 on Friday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $56.30. The stock has a market cap of $2.14 billion, a P/E ratio of 23.47, a PEG ratio of 0.81 and a beta of 0.80. The firm’s fifty day moving average price is $42.44 and its 200-day moving average price is $40.05.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio is 21.33%.

Analysts Set New Price Targets

A number of research firms recently weighed in on PAHC. JPMorgan Chase & Co. lifted their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $37.50.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks added PAHC to multiple Rank #1 (Strong Buy) lists — including momentum and value screens — which can attract short-term momentum traders and systematic buy programs. Best Momentum Stocks to Buy for February 20th New Strong Buy Stocks for February 20th Best Value Stocks to Buy for February 20th
• Positive Sentiment: Analyst models moved higher: Zacks Research has repeatedly raised quarterly and full‑year EPS forecasts (FY2026 to $2.96 from $2.73 and upgrades to FY2027/FY2028 estimates), signaling improved earnings visibility after the company’s February quarter beat and FY2026 guidance. That fundamental re-rating supports higher multiples. MarketBeat PAHC coverage
• Positive Sentiment: Recent fundamentals: Phibro beat Q4/quarterly estimates and gave FY2026 EPS guidance (2.93–3.10), and it declared a modest quarterly dividend — all supportive to investor confidence and institutional interest. MarketBeat PAHC coverage
• Neutral Sentiment: A Yahoo Finance piece flags valuation after the recent run — helpful context for investors assessing whether current gains are driven by fundamentals or short‑term momentum. It suggests caution on stretch valuations even as momentum persists. Assessing Phibro Animal Health (PAHC) Valuation After Strong Share Price Momentum
• Neutral Sentiment: Analyst mix remains mixed: despite estimate lifts, coverage is varied (several Holds, a few Buys and one Sell per MarketBeat), so upside depends on continued execution vs. elevated expectations. MarketBeat PAHC coverage
• Negative Sentiment: Insider selling: CEO Jack Bendheim has sold multiple sizable blocks in February (recent disclosures show several transactions at ~\$51–\$52), which some investors view as a negative signal on near‑term insider conviction. That selling can cap enthusiasm despite the other positives. Phibro Animal Health (NASDAQ:PAHC) CEO Sells $361,856.00 in Stock

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.